文献速递胸部肿瘤

阿替利珠单抗一线或后线治疗程序性死亡配体1选择的晚期非小细胞肺癌的II期试验(BIRCH)

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
PubMed 文献 · J Clin Oncol · 2017-06-13

BIRCH研究评估阿替利珠单抗在PD-L1选择的晚期非小细胞肺癌中的疗效,按治疗线数分三队列。独立评审客观缓解率在三队列为18%至22%,TC3或IC3亚组为26%至31%。中位总生存一线队列23.5个月,二线和三线及以上分别为15.5和13.2个月,耐受性良好。

要点

  • PD-L1≥5%肿瘤细胞或免疫细胞选择的晚期NSCLC患者接受阿替利珠单抗1200mg每3周一次。
  • 独立评审客观缓解率三队列为18%至22%,TC3或IC3亚组为26%至31%。
  • 一线队列中位总生存23.5个月,TC3或IC3患者26.9个月。

核心结论

  • BIRCH研究显示阿替利珠单抗单药在PD-L1选择的晚期非小细胞肺癌中具有缓解和良好耐受性,PD-L1状态可能作为预测生物标志物。

研究设计与样本

  • BIRCH为II期试验,纳入晚期非小细胞肺癌、无中枢神经系统转移、既往化疗零至二线及以上的患者,肿瘤PD-L1表达≥5%肿瘤细胞或免疫细胞(TC2/3或IC2/3)方可入组。
  • 阿替利珠单抗1200mg静脉给药每3周一次,疗效可评估患者N=659,分三队列:一线队列n=139,二线队列n=268,三线及以上队列n=252。
  • 主要终点为独立评审机构评估的客观缓解率(RECIST 1.1),次要终点包括中位缓解持续时间、无进展生存期和总生存期。

主要发现

  • 至少12个月随访时,独立评审机构评估的客观缓解率在三队列为18%至22%,在TC3或IC3亚组为26%至31%,多数缓解持续中。
  • 缓解发生于不论EGFR或KRAS突变状态的患者。
  • 更新生存分析(至少20个月随访)显示,一线队列中位总生存23.5个月(TC3或IC3患者26.9个月),二线队列15.5个月,三线及以上队列13.2个月。
  • 安全性特征在各队列间相似,与既往阿替利珠单抗单药试验一致。

关键数值与推荐

  • PD-L1表达采用SP142免疫组化检测,肿瘤细胞或免疫细胞≥5%阳性(TC2/3或IC2/3)定义入组人群。
  • 主要终点客观缓解率对比历史对照达到显著差异。
  • TC3或IC3亚组客观缓解率26%至31%,高于总体三队列的18%至22%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non-small-cell lung cancer (NSCLC) across lines of therapy. Patients were selected on the basis of PD-L1 expression on tumor cells (TC) or tumor-infiltrating immune cells (IC). Patients and Methods Eligible patients had advanced-stage NSCLC, no CNS metastases, and zero to two or more lines of prior chemotherapy. Patients whose tumors expressed PD-L1 using the SP142 immunohistochemistry assay on ≥ 5% of TC or IC (TC2/3 or IC2/3 [TC or IC ≥ 5% PD-L1-expressing cells, respectively]) were enrolled. Atezolizumab 1,200 mg was administered intravenously every 3 weeks. Efficacy-evaluable patients (N = 659) comprised three cohorts: first line (cohort 1; n = 139); second line (cohort 2; n = 268); and third line or higher (cohort 3; n = 252). The primary end point was independent review facility-assessed objective response rate (ORR; Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1). Secondary end points included median duration of response, progression-free survival, and overall survival (OS). Results BIRCH met its primary objective of demonstrating a significant ORR versus historical controls. With a minimum of 12 months of follow-up, the independent review facility-assessed ORR was 18% to 22% for the three cohorts, and 26% to 31% for the TC3 or IC3 subgroup; most responses are ongoing. Responses occurred regardless of EGFR or KRAS mutation status. The median OS from an updated survival analysis (minimum of 20 month follow up) for cohort 1 was 23.5 months (26.9 months for TC3 or IC3 patients); the median OS in cohorts 2 and 3 was 15.5 and 13.2 months, respectively. The safety profile was similar across cohorts and consistent with previous atezolizumab monotherapy trials. Conclusion BIRCH demonstrated responses with atezolizumab monotherapy in patients with PD-L1-selected advanced NSCLC, with good tolerability. PD-L1 status may serve as a predictive biomarker for identifying patients most likely to benefit from atezolizumab.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Peters S, Gettinger S, Johnson ML, et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017. PMID: 28609226. doi:10.1200/JCO.2016.71.9476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。